Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long COVID
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

March 2023

TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023

March 2023

mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs

January 2023

Primary vs Secondary Sex Hormones and Migraine

January 2023

Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy

December 2022

Live Virus Smallpox and Monkeypox Vaccine

November 2022

Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies

November 2022

In Vitro Impact of Oxytocin on Human Sensory Neurons

September 2022

Retrospective Observational Database Study of Patients with Long COVID with Multi-Site Pain, Fatigue, and Insomnia: A Real-World Analysis of Symptomatology and Opioid Use

September 2022

Monotherapy with TNX-1500, an Fc-modified Anti-CD154 mAb, Prolongs Cardiac Allograft Survival in Cynomolgus Monkeys

September 2022

Long-term (>1 year) Rejection/TMA Free Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Nonhuman Primates

Posts navigation

Older posts
Sign up for Email Alerts
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save your preferences, and provide us with information on how you use our website. For more information, please refer to our Privacy Policy. By accessing or using our website, you consent to our use of cookies. You may opt out of the use of cookies by adjusting your browser settings.

Accept